Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zylö Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life; and research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
IPO Year: 2019
Exchange: NASDAQ
Website: hoththerapeutics.com
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
3 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
Fastest customizable press release news feed in the world
NEW YORK, April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 2,857,144 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.70 per share of common stock (or per common stock equivalent in lieu thereof). Additionally, in a concurrent private placement, the Company issued and sold unregistered warrants to purchase up to an aggregate of 2,857,144 shares of common stock at an exercise price of $0.
NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,857,144 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.70 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering. Additionally, in a concurrent private placement, the Company issued and sold unregistered warrants to purchase up to an aggregate of 2,857,144 shares of common stock at an exercis
Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic ExposureNEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, today announced positive clinical results from its ongoing HT-001 program, including achievement of the primary efficacy endpoint in interim analysis, with patients reaching an ARIGA rash severity score of ≤1 by week six. In addition to the strong results in Ariga score, HT-001 demonstrated strong patient benefit across multiple cl
Technology Selectively Shuts Down Cancer Reproducing CellsPatent Covers Splice-Switching Oligonucleotide Platform Designed to Induce Apoptosis of Mast CellsNEW YORK, March 31, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced that the China National Intellectual Property Administration (CNIPA) has granted Chinese Patent, titled "Targeting Kit with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells." The patent, originally filed
NEW YORK, March 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, today announced the deployment of OpenClaw™, an advanced AI-enabled computational platform designed to accelerate drug discovery, enhance data-driven decision-making, and unlock value across its therapeutic pipeline. OpenClaw™ Activation Marks Strategic Shift Toward AI-Driven Drug DevelopmentThe launch of OpenClaw™ establishes a centralized, high-performance platform capable of integrating preclinical and clinical datasets in real time, enabling faster and
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations.Safety and tolerability findings included:No serious adverse events (0%)No dose-limiting toxicities observed.No treatment discontinuations due to adverse eventsDay 42 Data Show Higher AUC, Cavg, and Cmax vs Day 1, with ~2.1x Accumulation Supporting Sustained Drug Exposure, Consistent Tolerability, and Clinically Meaningful ResponseNEW YORK, March 24, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) today reported positive pharmacokinetic (PK), safety, and clinical activity data for HT-001, demonstrating a ~77% increase in systemic drug expos
HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female miceTreatment preserved hepatic autophagy and maintained normal liver cellular homeostasisFindings support continued development of HT-VA for metabolic dysfunction associated with obesity and MASLDNEW YORK, March 10, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs, today announced new female-specific preclinical results from the second phase of its metabolic disease study evaluating glial cell-derived neurotrophic factor (G
AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven CancersNEW YORK, March 4, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced the deployment of the OpenAI API to support IND-enabling development of HT-KIT, its orphan-designated therapy targeting rare and aggressive KIT-driven cancers. The OpenAI-powered API platform has been integrated into the HT-KIT development workflow to support preclinical data analysis, molecular modeling of K
CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment OptionNEW YORK, Feb. 24, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in Miami, Florida, Regis joins the growing CLEER-001 investigational site network as surging patient demand outpaces capacity at existing sites — a direct reflection of the compelling early clinical results HT-001 has produced and the desperate unmet need it addresses.
In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Administration GDNF demonstrated superior efficacy compared with semaglutide (the active ingredient in Wegovy®️ and Ozempic®️) across key metrics, including weight stabilization, glucose tolerance, liver weight reduction, and adipose tissue control—particularly in female models NEW YORK, Feb. 10, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company developing innovative therapies for unmet medical needs, today announced compelling preclinical data from its VA-backed study on glial cell-derived neurotrophic factor (GDNF) as a novel treatment for obesi
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
424B5 - Hoth Therapeutics, Inc. (0001711786) (Filer)
10-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
EFFECT - Hoth Therapeutics, Inc. (0001711786) (Filer)
424B5 - Hoth Therapeutics, Inc. (0001711786) (Filer)
10-Q - Hoth Therapeutics, Inc. (0001711786) (Filer)
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
Live Leadership Updates
Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK, June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event showcasing HT-001, its novel topical therapeutic, designed to treat debilitating skin toxicities caused by EGFR inhibitor cancer therapies. These common treatment-limiting side effects—suc
NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir
This live feed shows all institutional transactions in real time.
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)